References
- Centers for Disease Control and Prevention (U.S.). Antibiotic resistance threats in the USA, 2019 [Internet]. Centers for disease control and prevention (U.S.); 2019. [cited 2020 Jul 11]. Available from: https://stacks.cdc.gov/view/cdc/82532
- Ghebreyesus TA. Making AMR history: a call to action. Glob Health Action. 2019;12:1.
- Rogers BA, Sidjabat HE, Paterson DL. Escherichia coli O25b-ST131: a pandemic, multiresistant, community-associated strain. J Antimicrob Chemother. 2011;66:1–10.
- Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8:159–166.
- World Health Organization. Antibiotic resistance [Internet]. World Health Organization; 2020. [cited 2020 Aug 17]. Available from: https://www.who.int/news-room/fact-sheets/detail/antibiotic-resistance
- European Centre for Disease Prevention and Control, editor. The bacterial challenge, time to react: a call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. Stockholm: ECDC; 2009.
- Cassini A, Högberg LD, Plachouras D, et al. Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European economic area in 2015: a population-level modelling analysis. Lancet Infect Dis. 2019;19:56–66.
- de Kraker MEA, Stewardson AJ, Harbarth S. Will 10 million people die a year due to antimicrobial resistance by 2050? PLOS Med. 2016;13:e1002184.
- Adam RD. Antimicrobial resistance at a community level. Lancet Planet Health. 2018;2:e473–e474.
- Sanchez GV, Fleming-Dutra KE, Roberts RM, et al. Core elements of outpatient antibiotic stewardship. MMWR Recomm Rep. 2016;65:1–12.
- Bryce A, Costelloe C, Hawcroft C, et al. Faecal carriage of antibiotic resistant Escherichia coli in asymptomatic children and associations with primary care antibiotic prescribing: a systematic review and meta-analysis. BMC Infect Dis. 2016;16:359.
- Hanada S, Pirzadeh M, Carver KY, et al. Respiratory viral infection-induced microbiome alterations and secondary bacterial pneumonia. Front Immunol. 2018;9:2640.
- Allocati N, Masulli M, Alexeyev M, et al. Escherichia coli in Europe: an overview. Int J Environ Res Public Health. 2013;10:6235–6254.
- Salyers AA, Gupta A, Wang Y. Human intestinal bacteria as reservoirs for antibiotic resistance genes. Trends Microbiol. 2004;12:412–416.
- Blake DP, Hillman K, Fenlon DR, et al. Transfer of antibiotic resistance between commensal and pathogenic members of the Enterobacteriaceae under ileal conditions. J Appl Microbiol. 2003;95:428–436.
- Balkhy HH, Jarlier V, Kluytmans J, et al. Antimicrobial resistance: one world, one fight! Antimicrob resist infect control [Internet]; 2015. [cited 2017 Dec 17]. 4. Available from: https://aricjournal.biomedcentral.com/articles/10.1186/s13756-015-0091-2
- Hooton TM, Levy SB. Antimicrobial resistance: a plan of action for community practice. Am Fam Physician. 2001;63:1087–1098.
- Shamseer L, Moher D, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647.
- Ouzzani M, Hammady H, Fedorowicz Z, et al. Rayyan—a web and mobile app for systematic reviews. Syst Rev. 2016; [cited 2018 Apr 30]; 5. [Internet]. Available from. http://systematicreviewsjournal.biomedcentral.com/articles/10.1186/s13643-016-0384-4
- The System for the Unified Management. Assessment and review of information (SUMARI) [Internet]. Joanna briggs institute (JBI); [cited 2020 Jul 13]. Available from: https://auth.jbisumari.org
- Storberg V. ESBL-producing Enterobacteriaceae in Africa – a non-systematic literature review of research published 2008–2012. Infect Ecol Epidemiol. 2014;4:20342.
- Hedin A, Källestål C. Knowl-based public health work part 2 natl inst public health stockh. 2004.
- Bartoloni A, Cutts F, Leoni S, et al. Patterns of antimicrobial use and antimicrobial resistance among healthy children in Bolivia. Trop Med Int Health. 1998;3:116–123.
- Bartoloni A, Bartalesi F, Mantella A, et al. High prevalence of acquired antimicrobial resistance unrelated to heavy antimicrobial consumption. J Infect Dis. 2004;189:1291–1294.
- Bartoloni A, Pallecchi L, Benedetti M, et al. Multidrug-resistant commensal Escherichia coli in children, Peru and Bolivia. Emerg Infect Dis. 2006;12:907–913.
- Dyar OJ, Hoa NQ, Trung NV, et al. High prevalence of antibiotic resistance in commensal Escherichia coli among children in rural Vietnam. BMC Infect Dis. 2012;12:92.
- Kalter HD, Gilman RH, Moulton LH, et al. Risk factors for antibiotic-resistant Escherichia coli carriage in young children in Peru: community-based cross-sectional prevalence study. Am J Trop Med Hyg. 2010;82:879–888.
- Mamun KZ, Shears P, Hart CA. The prevalence and genetics of resistance to commonly used antimicrobial agents in faecal Enterobacteriaceae from children in Bangladesh. Epidemiol Infect. 1993;110:447–458.
- Purohit M, Chandran S, Shah H, et al. Antibiotic resistance in an Indian rural community: a ‘one-health’ observational study on commensal coliform from humans, animals, and water. Int J Environ Res Public Health. 2017;14:386.
- Shakya P, Barrett P, Diwan V, et al. Antibiotic resistance among Escherichia coli isolates from stool samples of children aged 3 to 14 years from Ujjain, India. BMC Infect Dis. 2013;13:477.
- Singh AK, Das S, Singh S, et al. Prevalence of antibiotic resistance in commensal Escherichia coli among the children in rural hill communities of Northeast India. PloS One. 2018;13:e0199179.
- Sahoo KC, Tamhankar AJ, Sahoo S, et al. Geographical variation in antibiotic-resistant Escherichia coli isolates from stool, cow-dung and drinking water. Int J Environ Res Public Health. 2012;9:746–759.
- Iorio A, Spencer FA, Falavigna M, et al. Use of GRADE for assessment of evidence about prognosis: rating confidence in estimates of event rates in broad categories of patients. BMJ. 2015;350:h870.
- Guyatt GH, Oxman AD, Kunz R, et al. GRADE guidelines: 7. Rating the quality of evidence–inconsistency. J Clin Epidemiol. 2011;64:1294–1302.
- Aworh MK, Kwaga J, Okolocha E, et al. Prevalence and risk factors for multi-drug resistant Escherichia coli among poultry workers in the federal capital territory, Abuja, Nigeria. PloS One. 2019;14:e0225379.
- Al-Dweik MR, Shehabi AA. Common antimicrobial resistance phenotypes and genotypes of fecal Escherichia coli isolates from a single family over a 6-month period. Microb Drug Resist Larchmt N. 2009;15:103–107.
- Hoang PH, Awasthi SP, DO Nguyen P, et al. Antimicrobial resistance profiles and molecular characterization of Escherichia coli strains isolated from healthy adults in Ho Chi Minh City, Vietnam. J Vet Med Sci. 2017;79:479–485.
- Lamikanra A, Ako-Nai AK, Ogunniyi DA. Transferable antibiotic resistance in Escherichia coli isolated from healthy Nigerian school children. Int J Antimicrob Agents. 1996;7:59–64.
- Lamikanra A, Fayinka ST, Olusanya OO. Transfer of low level trimethoprim resistance in faecal isolates obtained from apparently healthy Nigerian students. FEMS Microbiol Lett. 1989;59:275–278.
- Phongpaichit S, Liamthong S, Mathew AG, et al. Prevalence of class 1 integrons in commensal Escherichia coli from pigs and pig farmers in Thailand. J Food Prot. 2007;70:292–299.
- Roca I, Akova M, Baquero F, et al. The global threat of antimicrobial resistance: science for intervention. New Microbes New Infect. 2015;6:22–29.
- Magiorakos A-P, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect Off Publ Eur Soc Clin Microbiol Infect Dis. 2012;18:268–281.
- Pathak A, Mahadik K, Sharma R, et al. Factors associated with carriage of multi-resistant commensal Escherichia coli among postmenopausal women in Ujjain, India. Scand J Infect Dis. 2012;44:973–977.
- Riccobono E, Pallecchi L, Mantella A, et al. Carriage of antibiotic-resistant Escherichia coli among healthy children and home-raised chickens: a household study in a resource-limited setting. Microb Drug Resist Larchmt N. 2012;18:83–87.
- Iskandar K, Molinier L, Hallit S. et al. Drivers of antibiotic resistance transmissionin low- and middle-income countriesfrom a “one health” perspective – a review. Antibiot Basel Switz. 2020:9:372.
- Alekshun MN, Levy SB. Commensals upon us. Biochem Pharmacol. 2006;71:893–900.
- Global Action Plan on Antimicrobial Resistance [Internet]. World health organization; 2015. [cited 2020 Aug 17]. Available from: https://apps.who.int/iris/bitstream/handle/10665/193736/9789241509763_eng.pdf?sequence=1
- Haenssgen MJ, Charoenboon N, Zanello G, et al. Antibiotic knowledge, attitudes and practices: new insights from cross-sectional rural health behaviour surveys in low-income and middle-income South-East Asia. BMJ Open. 2019;9:e028224.
- Okba NMA, Müller MA, Li W, et al. Severe acute respiratory syndrome coronavirus 2−specific antibody responses in coronavirus disease 2019 patients. Emerg Infect Dis. 2020. [cited 2020 May 8]; 26. [Internet]. Available from: http://wwwnc.cdc.gov/eid/article/26/7/20-0841_article.htm
- Mitjà O, Clotet B. Use of antiviral drugs to reduce COVID-19 transmission. Lancet Glob Health. 2020;8:e639–e640.
- Poland GA. SARS-CoV-2: a time for clear and immediate action. Lancet Infect Dis. 2020;20:531–532.
- Li Z, Wang X, Cao D, et al. Rapid review for the anti-coronavirus effect of remdesivir. Drug Discov Ther. 2020;14:73–76.
- Meo SA, Klonoff DC, Akram J. Efficacy of chloroquine and hydroxychloroquine in the treatment of COVID-19. Eur Rev Med Pharmacol Sci. 2020;24:4539–4547.
- Hashem AM, Alghamdi BS, Algaissi AA, et al. Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: a narrative review. Travel Med Infect Dis. 2020;35:101735.
- Retsas S. Clinical trials and the COVID-19 pandemic. Hell J Nucl Med. 2020;23:4–5.
- Imhann F, Bonder MJ, Vich Vila A, et al. Proton pump inhibitors affect the gut microbiome. Gut. 2016;65:740–748.
- Jackson MA, Goodrich JK, Maxan M-E, et al. Proton pump inhibitors alter the composition of the gut microbiota. Gut. 2016;65:749–756.
- Rogers MAM, Aronoff DM. The influence of non-steroidal anti-inflammatory drugs on the gut microbiome. Clin Microbiol Infect. 2016;22:e1–178.e9.
- Bandera A, De Benedetto I, Bozzi G, et al. Altered gut microbiome composition in HIV infection: causes, effects and potential intervention. Curr Opin HIV AIDS. 2018;13:73–80.
- Monaco CL, Gootenberg DB, Zhao G, et al. Altered virome and bacterial microbiome in human immunodeficiency virus-associated acquired immunodeficiency syndrome. Cell Host Microbe. 2016;19:311–322.
- Blaser MJ. Antibiotic use and its consequences for the normal microbiome. Science. 2016;352:544–545.
- Bonten MJM, Prins JM. Antibiotics in pandemic flu. BMJ. 2006;332:248–249.
- Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. 2020;ciaa530. DOI:10.1093/cid/ciaa530
- Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis. 2008;198:962–970.
- Cooke P, Shrestha A, Arjyal A, et al. What is ‘antimicrobial resistance’ and why should anyone make films about it? Using ‘participatory video’ to advocate for community-led change in public health. New Cine J Contemp Film. 2020;17:85–107.
- Aslam B, Wang W, Arshad MI, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645–1658
- King R, Hicks J, Rassi C, et al. Community Dialogue Approach for addressing the drivers of antibiotic resistance in Bangladesh: a mixed methods study on developing a sustainable and scalable approach to community engagement [Internet]. In Review; 2020. [cited 2020 Aug 18]. Available from: https://www.researchsquare.com/article/rs-15638/v1